Apixaban: an Oral Direct Factor-Xa Inhibitor

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Advances in Therapy

• Publication date

  2012-02-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s12325-012-0003-2PMID 22354465
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Apixaban versus Warfarin in Patients with Atrial Fibrillation

  2012cited by this paper
• Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

  2012cited by this paper
• The Role of Apixaban for Venous and Arterial Thromboembolic Disease

  2011cited by this paper
• Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor

  2011cited by this paper
• Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor

  2011cited by this paper
• Apixaban in patients with atrial fibrillation.

  2011cited by this paper
• Apixaban with antiplatelet therapy after acute coronary syndrome.

  2011cited by this paper
• Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.

  2011cited by this paper
• Outpatient management of acute deep vein thrombosis: results from the OTIS-DVT registry.

  2011cited by this paper
• Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.

  2011cited by this paper
• Apixaban versus warfarin in patients with atrial fibrillation.

  2011cited by this paper
• Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: Comparison with direct inhibitors of factor VIIa, XIa and thrombin

  2010influential reference
• Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients

  2010cited by this paper
• Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial.

  2010influential reference
• In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies

  2010cited by this paper
• Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism.

  2010cited by this paper
• Out of hospital anticoagulant therapy in patients with acute pulmonary embolism is frequently practised but not perfect.

  2010cited by this paper
• Apixaban versus enoxaparin for thromboprophylaxis after hip replacement.

  2010cited by this paper
• Apixaban versus enoxaparin in patients with total knee arthroplasty

  2010cited by this paper
• Apixaban or enoxaparin for thromboprophylaxis after knee replacement.

  2009cited by this paper
• Apixaban Metabolism and Pharmacokinetics after Oral Administration to Humans

  2009cited by this paper
• Different Characteristics of Direct Factor Xa Inhibitors: In Vitro Comparative Studies of Rivaroxaban and Apixaban.

  2009cited by this paper
• Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial

  2009cited by this paper
• Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study

  2008influential reference
• Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

  2008influential reference
• Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Antithrombotic and Thrombolytic Therapy. American College of Chest Physicans Guidelines – 2008

  2008cited by this paper
• Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

  2008cited by this paper
• Venous thromboembolism (VTE) in Europe

  2007cited by this paper
• Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

  2007cited by this paper
• Derivation and validation of a prognostic model for pulmonary embolism.

  2005cited by this paper
• Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients

  2005cited by this paper
• Systematic overview of warfarin and its drug and food interactions.

  2005cited by this paper
• Warfarin and Other Coumarin Derivatives: Pharmacokinetics, Pharmacodynamics, and Drug Interactions

  2003cited by this paper
• Natural History of Venous Thromboembolism

  2003cited by this paper
• Prevention of venous thromboembolism.

  2001cited by this paper
• Meta-analyses of randomised controlled trials.

  1997cited by this paper
• Thrombolysis in myocardial infarction (TIMI) trial: Phase I. A comparison between intravenous tissue plasminogen activator and intravenous streptokinase

  1988cited by this paper
• Thrombolysis inMyocardial Infarction (TIMI) Trial, Phase I:acomparison between intravenous tissue plasminogen activator andintravenous streptokinase*

  1987cited by this paper
• Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge.

  1987cited by this paper
• Warfarin metabolism and drug-drug interactions.

  1987cited by this paper

• Navigating the Complexities of Apixaban on INR Values: Inadvertent Lab Insights From a Real‐World Experience

  2026cites this paper
• Effective Management Strategies for Dental Patients on Anticoagulants: Ensuring Optimal Care and Patient Safety: An Overview

  2025cites this paper
• Comparative Cardioprotective Effectiveness: NOACs vs. Nattokinase—Bridging Basic Research to Clinical Findings

  2024cites this paper
• Effective Apixaban removal using hemoadsorption during emergent open-heart surgery: a case report and narrative literature review

  2024cites this paper
• Does amiodarone impact on apixaban levels? The effect of amiodarone on apixaban level among Thai patients with non-valvular Atrial Fibrillation

  2024cites this paper
• Factor Xa inhibitors versus warfarin in patients with non-valvular atrial fibrillation and diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

  2024cites this paper
• Anticoagulants in Children with Renal Impairment: A Narrative Review

  2024cites this paper
• A practical synthesis for the key intermediate of apixaban

  2023cites this paper
• Risk of Bleeding in Liver Cirrhosis Receiving Direct Oral Anticoagulants: A Systematic Review and Meta-analysis

  2023cites this paper
• A thrombophilic allele of clotting Factor VII/VIIa promoting recurrent pulmonary emboli, clinical details, and a structural model of the altered protein: a case report

  2023cites this paper
• Esomeprazole and apixaban pharmacokinetic interactions in healthy rats

  2022cites this paper
• Preparation and blood compatibility of polyethersulfone dialysis membrane modified by apixaban as coagulation factor Xa inhibitor.

  2022cites this paper
• Use of direct oral anticoagulants in ICU patients. Part I - Applied pharmacology.

  2021cites this paper
• S3 guideline: Management of anticoagulants and antiplatelet agents in cutaneous surgery

  2021cites this paper
• S3‐Leitlinie: Umgang mit Antikoagulanzien und Thrombozytenaggregationshemmern bei Operationen an der Haut

  2021cites this paper
• Apixaban Does Not Interfere With Protein S or Activated Protein C Resistance (Factor V Leiden) Testing Using aPTT-Based Methods.

  2020cites this paper
• The effect of anticoagulants on delayed bleeding after colorectal endoscopic submucosal dissection

  2019cites this paper
• A REVIEW ON A COMPARATIVE STUDY ON EFFECTIVENESS AND SAFETY OF NOVEL ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION

  2019cites this paper
• Guidelines for Gastroenterological Endoscopy in Patients Undergoing Antithrombotic Treatment: 2017 Appendix on Anticoagulants Including Direct Oral Anticoagulants

  2018cites this paper
• A simple and fast HPLC-MS/MS method for simultaneous determination of direct oral anticoagulants apixaban, dabigatran, rivaroxaban in human plasma.

  2018cites this paper
• Antithrombotic Stewardship: Assessing Use of Computerized Clinical Decision Support Tools to Enhance Safe Prescribing of Direct Oral Anticoagulants in Hospitalized Patients

  2018cites this paper
• Rapid Reversal of Novel Anticoagulant and Antiplatelet Medications in General Surgery Emergencies.

  2018cites this paper
• International Normalized Ratio Is Significantly Elevated With Rivaroxaban and Apixaban Drug Therapies: A Retrospective Study.

  2017cites this paper
• Practical perspectives on the use of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation: A view from the Middle East and North Africa

  2017cites this paper
• Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.

  2017cites this paper
• Advances in anticoagulation management of patients undergoing cardioversion of nonvalvular atrial fibrillation

  2017cites this paper
• Identification of AcAP5 as a novel factor Xa inhibitor with both direct and allosteric inhibition.

  2017cites this paper
• Apixaban: Effective and Safe in Preventing Thromboembolic Events in Patients with Atrial Fibrillation and Renal Failure.

  2017cites this paper
• Apixaban: A Review in Venous Thromboembolism

  2016cites this paper
• Přímá perorální antikoagulancia

  2016cites this paper
• Anticoagulantes orales directos para el tratamiento de los pacientes con fibrilación auricular no valvular

  2016cites this paper
• NOVOS FÁRMACOS ANTICOAGULANTES ORAIS ALTERNATIVOS À VARFARINA

  2015cites this paper
• Determination of potential main sites of apixaban binding in human serum albumin by combined spectroscopic and docking investigations

  2015cites this paper
• Measurement of Anti-Factor Xa Activity in Patients on Apixaban for Non-Valvular Atrial Fibrillation.

  2015cites this paper
• Gerinnungsmonitoring – praktisches Management

  2014cites this paper
• Research Progress of Warfarin-associated Vascular Calcification and Its Possible Therapy

  2014cites this paper
• Direct oral anticoagulants: integration into clinical practice

  2014cites this paper
• Association of apixaban therapy and prothrombin time in patients with atrial fibrillation.

  2014cites this paper
• NewOral Anticoagulants for Thromboprophylaxis after Elective Total Hip and Knee Arthroplasty

  2014cites this paper
• Novel Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation

  2014cites this paper
• A Novel Prothrombin Time Assay for Assessing the Anticoagulant Activity of Oral Factor Xa Inhibitors

  2013cites this paper
• Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

  2013cites this paper
• Practical management of new oral anticoagulants after total hip or total knee arthroplasty

  2013cites this paper
• Novel oral anticoagulants: clinical pharmacology, indications and practical considerations

  2013cites this paper
• Use of New Oral Anticoagulants in Antiphospholipid Syndrome

  2013cites this paper
• Pharmacology of the new target-specific oral anticoagulants

  2013cites this paper
• Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment

  2013cites this paper
• Monograph apIXaBan In ThE prEVEnTIon oF STroKE anD SYSTEMIC EMBoLISM In nonVaLVULar aTrIaL FIBrILLaTIon

  2013cites this paper
• Measuring or Monitoring of Novel Anticoagulants: Which Laboratory Test to Request?

  2013cites this paper
• Консервативная терапия острого коронарного синдрома у больных сахарным диабетом 2 типа

  2013cites this paper
• The use of novel oral anticoagulants for thromboprophylaxis after elective major orthopedic surgery

  2013cites this paper
• Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors.

  2013cites this paper
• Newer anticoagulants for the prevention of venous thromboembolism.

  2012cites this paper
• Stroke Prevention in Atrial Fibrillation: Where are We Now?

  2012cites this paper
• Renal Profiles of Anticoagulants

  2012cites this paper
• Current Status of New Anticoagulants in the Management of Venous Thromboembolism

  2012cites this paper
• Efficacy and safety of venous thromboembolism prophylaxis with apixaban in major orthopedic surgery

  2012cites this paper
• New Oral Anticoagulants in Surgery

  2012cites this paper
• Safety and Efficacy of Apixaban in the Treatment of Atrial Fibrillation

  2012cites this paper
• Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

  2012cites this paper
• Implementing the new oral anticoagulants into the hospital formulary

  2012cites this paper
• Oral Factor Xa and Direct Thrombin Inhibitors: A Clinical Perspective

  2012cites this paper
• Stroke Prevention in Atrial Fibrillation: Concepts and Controversies

  2012cites this paper
• Venous Thromboembolism in Neonates, Children and Patients with Chronic Renal Disease – Special Considerations

  2012cites this paper
• Breakthroughs in anticoagulation: advent of the oral direct factor Xa inhibitors.

  2012cites this paper
• Clinical experience with apixaban in atrial fibrillation: implications of AVERROES

  2011cites this paper
• Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban

  2011cites this paper
• Apixaban

  2011influential citation
• The potential role of new oral anticoagulants in the prevention and treatment of thromboembolism.

  2011cites this paper
• The Role of Apixaban for Venous and Arterial Thromboembolic Disease

  2011cites this paper
• Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor

  2011cites this paper
• Drug and dietary interactions of warfarin and novel oral anticoagulants: an update

  2011cites this paper
• Laboratory assessment of new anticoagulants

  2011cites this paper
• New oral anticoagulants

  2011cites this paper
• In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies

  2010cites this paper
• Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: Comparison with direct inhibitors of factor VIIa, XIa and thrombin

  2010cites this paper
• New Oral Anticoagulants for Thromboprophylaxis after Elective Total Hip and Knee Arthroplasty

  2010cites this paper
• Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development

  2010influential citation
• Factor Xa inhibitors: next-generation antithrombotic agents.

  2010cites this paper
• Clinical laboratory measurement of direct factor Xa inhibitors: Anti-Xa assay is preferable to prothrombin time assay

  2010cites this paper
• Quantification of Apixaban's Therapeutic Utility in Prevention of Venous Thromboembolism: Selection of Phase III Trial Dose

  2010cites this paper
• Assays for Measuring Rivaroxaban: Their Suitability and Limitations

  2010cites this paper
• Current and Emerging Anticoagulant Agents for the Prevention and Treatment of Ischemic Stroke: Focus on Dabigatran

  2010cites this paper
• Send Orders of Reprints at Reprints@benthamscience.org Stroke Prevention in Atrial Fibrillation: Concepts and Controversies

  year unknowncites this paper